MedPath

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Primary Open Angle Glaucoma
Ocular Hypertension
Interventions
Registration Number
NCT05022004
Lead Sponsor
Sun Pharmaceutical Industries Limited
Brief Summary

This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
599
Inclusion Criteria
  • Male or nonpregnant female aged 18 years or older with chronic open angle glaucoma or ocular hypertension in both eyes.
  • Provide signed and dated informed consent in accordance with good clinical practice and local legislation prior to any study procedure.
  • Be able and willing to follow study instructions and complete all required visits.
  • Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
Exclusion Criteria
  • Subjects with angle closure glaucoma
  • Females who are pregnant, breast feeding, or planning a pregnancy.
  • Females of childbearing potential who do not agree to utilize an adequate form of contraception.
  • Current, or past history of, severe hepatic or renal impairment
  • Current, or history within 2 months prior to baseline of, significant ocular disease
  • Functionally significant visual field loss
  • Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy
  • Subjects currently in another clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BRIN-20-01Brinzolamide ophthalmic suspension-
Azopt®Azopt®-
Primary Outcome Measures
NameTimeMethod
Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment GroupsBaseline, Week 2 & Week 6

The recommended primary endpoint is the mean difference in Intraocular Pressure of both eyes between the two treatment groups at pre-specified time points.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in IOP of Both Eyes Between the 2 Treatment Groups.approximately 8:00 AM. (hour 0; before the morning drop) and 10:00 AM. (hour 2) at the Day 14 (Week 2) and Day 42 (Week 6) visits

Trial Locations

Locations (34)

Dr. BR Ambedkar Medical College and hospital

🇮🇳

Bangalore, Karnataka, India

Rising Retina Clinic

🇮🇳

Ahmedabad, Gujarat, India

Dr Agarwal's Eye Hospital

🇮🇳

Tirunelveli, Tamil Nadu, India

Heritage Institute of Medical Sciences

🇮🇳

Varanasi, Uttar Pradesh, India

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

🇷🇺

Volgograd, Russian Federation

Healthcare Organization "Eye Center", Limited Liability Company

🇷🇺

Chelyabinsk, Russian Federation

Bhagwan Mahaveer Jain Hospital

🇮🇳

Bangalore, Karnataka, India

KLE's Dr. Prabhakar Kore Hospital & Medical Research Center

🇮🇳

Belgaum, Karnataka, India

Sankara Nethralaya

🇮🇳

Chennai, Tamil Nadu, India

Moscow Medical university n.a. Sechenov

🇷🇺

Moscow, Russian Federation

Ivanovo Regional Clinical Hospital

🇷🇺

Ivanovo, Russian Federation

"Eye Microsurgery" n a Academician S.N. Fedorov"

🇷🇺

Kaluga, Russian Federation

Feral State Budgetary Healthcare Institution "Clinical Hospital No. 122 named after L.G. Sokolov of the Federal Medical and Biological Agency"

🇷🇺

Saint Petersburg, Russian Federation

Ulyanovsk ophthalmology clinical "Prozrenie"

🇷🇺

Ulyanovsk, Russian Federation

Republican clinical ophthalmological hospital of Ministry of Health of Republic of Tatarstan named after E.V. Adamyuk

🇷🇺

Kazan, Republic Of Tatarstan, Russian Federation

GMC, Srikakulam

🇮🇳

Srikakulam, Andhra Pradesh, India

Bhavna Super speciality Eye care

🇮🇳

Surat, Gujarat, India

Shanti Saroj Netralay

🇮🇳

Miraj, Maharashtra, India

Acharya Vinoba Bhave Rural Hospital, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences

🇮🇳

Wardha, Maharashtra, India

Omkar Eye Care Center

🇮🇳

Mumbai, Maharashtra, India

Institute of Human Brain of the Russian Academy of Science, 197376, Academ. Pavlov street 12 AP, StPetersburg, Russia

🇷🇺

Saint Petersberg, Saint Petersburg, Russian Federation

"Angris", Limited Liability Company

🇷🇺

Moscow, Russian Federation

"X7 Clinical Research", Limited Liability Company

🇷🇺

Saint Petersburg, Russian Federation

"Moscow Regional Clinical Research Institute named after M.F. Vladimirsky"

🇷🇺

Moscow, Russian Federation

Federal budgetary healthcare institution Privolzhsky district medical center FMBA of Russia.

🇷🇺

Nizhny Novgorod, Russian Federation

Budgetary Healthcare Institution of the Omsk Region "Clinical Eye Hospital named after V.P. Vykhodtsev

🇷🇺

Omsk, Russian Federation

Federal Budgetary Healthcare Institution "Volga Region Medical Centre" of the Federal Medical and Biological Agency

🇷🇺

Novgorod, Russian Federation

Samara medical university

🇷🇺

Samara, Russian Federation

Nongovernmental Healthcare Institution "Clinical Hospital "RZhD [Russian Railways]-

🇷🇺

Saratov, Russian Federation

State Budgetary Institution "Ufa Research Institute of Eye Diseases of the Academy of Sciences of the Republic of Bashkortostan

🇷🇺

Ufa, Russian Federation

ZAO "Optimedservice"

🇷🇺

Ufa, Russian Federation

Federal State Budgetary Educational Institution of Higher Education "Moscow State University of Medicine and Dentistry named after A.I. Evdokimov" of the Ministry of Healthcare of the Russian Federation

🇷🇺

Moscow, Russian Federation

Dr. RSPR Govt Regional Eye Hospital; Vishakapatnam

🇮🇳

Visakhapatnam, Andhra Pradesh, India

K R Hospital, Mysore Medical College and Research Institute

🇮🇳

Mysuru, Karnataka, India

© Copyright 2025. All Rights Reserved by MedPath